The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Myocardial Inflammation Associated with RA Disease Activity

Myocardial Inflammation Associated with RA Disease Activity

March 28, 2019 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Introduction: Heart failure, a key contributor to cardiovascular disease (CVD) morbidity and mortality, is associated with fewer symptoms and higher (preserved) ejection fraction, but higher mortality rates, in rheumatoid arthritis (RA) patients than among those in the general population.

You Might Also Like
  • Myocardial Inflammation Elevated in Active RA, Eases with DMARD Therapy
  • Autoimmune Inflammation Increases Risk of Heart Disease
  • Therapies Aimed at Immune Cell Progenitors May Be Key to Reducing Post Myocardial Infarction Risk

In the general population, higher levels of circulating proinflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin 6 (IL-6), are independent predictors of heart failure. In rodents, infusion of TNF reduced myocardial contractility and cardiac-specific overexpression of a TNF transgene is associated with myocardial inflammation, remodeling, fibrosis and eventually heart failure. In RA patients, circulating levels of TNF and IL-6 are orders of magnitude higher than those shown to predict heart failure in the general population; however, little is known about inflammatory processes within the RA myocardium itself.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Autopsy studies of RA hearts from the mid-20th century suggested that myocarditis may occur in 15–20% of RA patients. However, contemporary histologic characterization studies of the myocardium in RA patients are few, mostly limited to patients with a known history of ischemic CVD.

The conventional gold standard for diagnosing myocarditis is endomyocardial biopsy. However, its sensitivity is limited by the heterogeneous distribution of myocarditis. This, coupled with its invasiveness, expense and risk of complications, has limited investigations of subclinical myocarditis in patients with RA. Cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) has been used to identify myocardial abnormalities, but clinically approved gadolinium-based contrast agents distribute to the extracellular space and are not taken up by cells. Thus, myocardial LGE reflects interstitial edema, but cannot directly identify inflammatory infiltrates, nor can LGE identify diffuse myocardial involvement, only focal.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

CMR T2-weighted imaging (T2WI), a more sensitive method for measuring myocardial edema that is not dependent on gadolinium, may detect diffuse myocardial involvement but does specifically indicate inflammatory cellular infiltration.

In recent years, 18-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET-CT) has been shown to have high sensitivity for detecting myocardial inflammation.

Objective: These researchers set out to determine the prevalence and correlates of subclinical myocardial inflammation in patients with RA.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Methods: RA patients (n=119) without known cardiovascular disease underwent cardiac FDG PET-CT. Myocardial FDG uptake was assessed visually and measured quantitatively as the standardized uptake value (SUV). Multivariable linear regression was used to assess the associations of patient characteristics with myocardial SUVs. A subset of RA patients who had to escalate their disease-modifying antirheumatic drug (DMARD) therapy (n=8) underwent a second FDG PET-CT scan after six months, to assess treatment-associated changes in myocardial FDG uptake.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Arthritis & Rheumatology, cardiovascular, Cardiovascular disease, heart

You Might Also Like:
  • Myocardial Inflammation Elevated in Active RA, Eases with DMARD Therapy
  • Autoimmune Inflammation Increases Risk of Heart Disease
  • Therapies Aimed at Immune Cell Progenitors May Be Key to Reducing Post Myocardial Infarction Risk
  • No Clear Connection Between Inflammation & Disease Progression in AS

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.